(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline.
This meets the minimum requirement for their exchange offer. Now, BioNTech will provide ADSs or cash for any fractional ADSs to the shareholders who participated, and they've also opened up another offering period until December 18.
Once that period wraps up, they'll go ahead with a post-offer reorganization.
BNTX is currently trading at $97.01, up $0.90 or 0.94 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
